Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin lispro Clear all
Completed Phase 2Phase 3 Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study

NCT03565666
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care
Device · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

NCT01216618
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

NCT05325294
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed 780G System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 1 Diabetes Mellitus

NCT01481779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Concord, California • Escondido, California • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

NCT01109316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Results available

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

NCT01810952
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus
Interventions
Glargine insulin, Lispro insulin, NPH Insulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

NCT00071448
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin human, insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NCT01621776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Apidra, Humalog, Novolog
Drug
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 14 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
DeLeon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

NCT04537923
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Insulin Lispro (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

NCT00191464
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
premeal insulin lispro mixtures, insulin glargine, metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
35 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT03367390
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT00700622
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Technosphere Insulin, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

NCT00607087
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin glulisine, Insulin lispro, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges

NCT03848767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 24, 2026, 8:21 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT03156361
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional

Insulin Therapy in the Hospital Comparing Two Protocols

NCT00841919
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 24, 2026, 8:21 AM EDT